The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Alert ISMP. Confusion regarding the generic name of the HER2-targeted drug KADCYLA (ado-trastuzumab emtansine). April 17, 2013. http://www.ismp.org/NAN/files/20130417.pdf. Accessed July 9, 2013.
3.
Lewis-PhillipsGDLiGDuggerDL. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290.
4.
GirishSGuptaMWangB. Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69(5):1229–1240.
5.
KropIEBeeramMModiS. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698–2704.
6.
BeeramMKropIEBurrisHAGirishSR. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer.2012;118(23):5733–5740.
BurrisHARugoHSVukeljaSJ. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.
9.
KropIELoRussoPMillerKD. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30(26):3234–3241.
10.
VermaSMilesDGianniL. Trastuzumab emtansine for HER2-positive advanced breast cancer [erratum published in N Engl J Med. 2013;368(25):2442]. N Engl J Med. 2012;367(19):1783–1791.
11.
HurvitzSADirixLKocsisJ. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157–1163.
12.
McDevittMRSgourosGFinnRD. Radioimmunotherapy with alpha-emitting particles. Eur J Nucl Med. 1998;25(9):1341–1351.
13.
LewingtonVJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(1 Suppl):38S-46S.
14.
Bruland ØSNilssonSFischerDR. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?Clin Cancer Res. 2006;12(20 Pt 2):6250s-6257s.
15.
HenricksenGBreistølKBruland ØS. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res.2002;62(11):3120–3125.
16.
AlpharadinLiepeK, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009;10(12):1346–1358.
17.
KerrC.(223) Ra targets skeletal metasteses and spares normal tissue. Lancet Oncol. 2002;3(8):453.
18.
HenriksenGFisherDRRoeskeJC. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–259.
NilssonSLarsenRHFossåSD. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–4459.
21.
NilssonSFranzénLParkerC. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–594.
22.
NilssonSStrangPAksnesAK. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678–686.
23.
ParkerCCPascoeSChodackiA. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63(2):189–197.
24.
MorrisMJCarrasquilloJAO'DonoghueJA. Phase I pharmacokinetic (PK) and biodistribution study with escalating doses of radium-223 in men with castration-resistant metastatic prostate cancer (CRMPC) [abstract 211]. Presented at: Genitourinary Cancers Symposium 2010.http://meetinglibrary.asco.org/content/30493-73. Accessed July 9, 2013.
25.
ParkerCGarcia-VargasJEO'Bryan-TearCG. Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial[abstract 5060]. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. http://meetinglibrary.asco.org/content/113243-132. Accessed July 9, 2013.
